丹参川芎嗪注射液辅助治疗对顽固性高血压患者血清CRP及同型半胱氨酸水平影响研究

doi:10.3969/j.issn.1006-6233.2018.02.012

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1317 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the effect of Salvia miltiorrhiza Ligustrazine Injection in the treatment of Refractory hypertension in elder in serum CRP and homocysteine. Methods: 90 cases with refractory hypertension in our hospital were selected and divided into 2 groups, 44 cased in the control group received irbesartan and hydrochlorothiazide treatment, 44 cases in the treatment group received more with Salvia miltiorrhiza Ligustrazine Injection treatment, a total of 14 days treatment. Changes of laboratory indexes were compared to explore the clinical effect and mechanism of the Salvia miltiorrhiza Ligustrazine Injection in the treatment of Refractory hypertension. Results: After 14 days of treatment, diastolic blood pressure and systolic blood pressure in 2 groups were significantly decreased than before(P<0.05), and the average blood pressure in the treatment group was lower than the control group(P<0.05). After 14 days of treatment, the total effective rate of the treatment group was significantly higher than the control group(P<0.05). Before treatment, two groups of CRP, Hcy, whole blood viscosity, whole blood low shear viscosity was no significant difference after treatment, CRP, Hcy, whole blood viscosity, whole blood low shear viscosity of treatment group improvement were better than the control group, there was significant difference between two groups. (P<0.05). Conclusion: Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection adjuvant therapy can significantly improve serum CRP and homocysteine levels in patients with refractory hypertension, and it has good clinical therapeutic effect.

Key words： Salvia miltiorrhiza Ligustrazine Injection Resistant hypertension Homocysteine C-reactive protein

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.02.012 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I2/228

[1] Chen W W, Cheng X, Zhang X, et al. The expression features of serum Cystatin C and homocysteine of Parkinson's disease with mild cognitive dysfunction.[J]. European Review for Medical & Pharmacological Sciences, 2015, 19(16):2957~2963.
[2] Li X, Huang S, Zhou S. Correlation between hypertensive disorder complicating pregnancy with homocysteine,D-D and hs-CRP[J]. International Journal of Laboratory Medicine, 2014.
[3] 闫登魁.疏血通注射液治疗急性脑梗死的临床疗效及对患者血清Hcy、hs-CRP的影响[J].中西医结合心脑血管病杂志,2011,9(12):1451~1452.
[4] Li X, Huang S, Zhou S. Correlation between hypertensive disorder complicating pregnancy with homocysteine,D-D and hs-CRP[J]. International Journal of Laboratory Medicine, 2014.
[5] 张璐.脑心通胶囊联合丹红注射液对不稳定型心绞痛患者血清超敏C反应蛋白及同型半胱氨酸的影响[J].山西医药杂志,2014,(23):2787~2788.
[6] 刘金柱,王铁,赵远贵,等.丹参川芎嗪注射液对老年不稳定型心绞痛患者的疗效和对血清hs-CRP、血脂的影响[J].中药药理与临床,2015,(4):237~239.
[7] 麻京豫.丹红注射液对冠心病不稳定型心绞痛的临床疗效及对患者Hcy、hs-CRP、NT-proBNP的影响研究[J].中药药理与临床,2015,(1):232~234.
[8] 席伟,王建生,张明洁.丹参川芎嗪注射液治疗妊娠期高血压疾病对患者Hcy和vWF水平的影响[J].微循环学杂志,2013,23(3):35~36.
[9] 吴华伟,刘仁斌.不同剂量川芎嗪辅助治疗对缺血性脑血管疾病患者血清C反应蛋白和同型半胱氨酸水平的影响[J].实用心脑肺血管病杂志,2015,(6):88~90.
[10] 林玉全,王升武.依达拉奉对脑梗死患者血清高敏C反应蛋白和同型半胱氨酸的影响[J].临床和实验医学杂志,2010,9(2):99~100.
[11] 刘丰.依达拉奉联合丹参注射液对急性脑梗死患者血清Hcy的影响[J].中国临床研究,2014,27(12):1485~1486.
[12] 张晓慧.中西医结合治疗对原发性高血压患者血清UA、Hcy、hs-CRP及血脂水平的影响[J].现代中西医结合杂志,2016,(7):733~735.
[13] 罗昔金,刘小阳,肖潇.瑞舒伐他汀联合叶酸对高血压患者同型半胱氨酸、胱抑素C及高敏C反应蛋白水平的影响[J].医学临床研究,2016,33(3).
[14] 黄辉传,刘国超.丹参注射液联合依达拉奉治疗急性脑梗死的临床疗效及对血浆同型半胱氨酸水平和日常活动能力的影响研究[J].实用心脑肺血管病杂志,2016,(6).
[15] 高宇,折瑞莲,黎燕.硫酸镁联合硝苯地平治疗对妊娠期高血压疾病患者血清Hcy和CRP的影响[J].中国妇幼保健,2014,29(6):859~861.